Skip to content

Study · Measured the body's own peptide · 2008

1 result

Reproductive hormones in plasma over the menstrual cycle in primary dysmenorrhea compared with healthy subjects.

Liedman R, Hansson SR, Howe D, Igidbashian S, McLeod A, Russell RJ, Akerlund M

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology1 Sept 2008Cited by 42 (Europe PMC)

PMID18958771 (opens in a new tab)DOI10.1080/09513590802306218 (opens in a new tab)PepBankPUB-18958771
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Natural levels measured1

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelObservational studyOther

    In women with primary dysmenorrhea, plasma oxytocin was higher at menstruation than in healthy women.

    In plain wordsIn women with primary dysmenorrhea, the body's own oxytocin level was higher at menstruation than in healthy women.

    Peptide
    Oxytocin
    Outcome
    IncreasePlasma oxytocin at menstruation
    Study

    n = 16

    Comparator
    Healthy volunteers
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health

    Source sentences

    Summary
    In dysmenorrheic women the plasma concentration of oxytocin was significantly higher at menstruation (p = 0.0084)
    1 context sentence
    Summary · context
    In a prospective, parallel-group study we determined the plasma concentrations of oxytocin, vasopressin, follicle-stimulating hormone (FSH), luteinizing hormone (LH), 17beta-estradiol (17beta-E2), progesterone and prostaglandin F 2alpha metabolite (15-keto-13,14-dihydro-PGF 2alpha) over one menstrua…

    This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 1NCT02893722

A Randomized Double Blind Comparison of Atosiban in Patients With RIF Undergoing IVF Treatment

Shanghai First Maternity and Infant Hospitaln = 200Jan 2017 to est. Dec 2018

Repeated Implantation Failure

Trial pageClinicalTrials.govUpdated 8 Sept 2016

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.